Aktuellt
SENASTE
Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view. Sales are still low as expected, and costs are maintained at reasonable levels. We are making minor adjustments to our estimates as we roll over our DCF model. We reiterate our fair value range of SEK 10 to 28 per share with a Base case of SEK 18 per share.
LÄS MER
